Progression from MCI to AD: Predictive value of CSF Aβ42 is modified by APOE genotype

Neurobiology of Aging

Volumn 32, Issue 8, 2011, Pages 1372-1378

  Kester, Maartje I ^a   Verwey, Nicolaas A ^a   van Elk, Evert J ^a   Blankenstein, Marinus A ^a   Scheltens, Philip ^a   van der Flier, Wiesje M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; APOE genotype; Biomarkers; CSF; MCI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; APOE EPSILON 4 GENE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE INTERACTION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK ASSESSMENT; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; DISEASE PROGRESSION; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 79959581630     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.08.006     Document Type: Article

References (37)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C.M., Miura M., Machida N., Lee V.M., Trojanowski J.Q., Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 1997, 236:262-264.
3. Beeri M.S., Rapp M., Silverman J.M., Schmeidler J., Grossman H.T., Fallon J.T., Purohit D.P., Perl D.P., Siddiqui A., Lesser G., Rosendorff C., Haroutunian V. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 2006, 66:1399-1404.
4. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
5. Bouwman F.H., Schoonenboom N.S., Verwey N.A., van Elk E.J., Kok A., Blankenstein M.A., Scheltens P., van der Flier W.M. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2007.08.010.
6. Bouwman F.H., Schoonenboom S.N., van der Flier W.M., van Elk E.J., Kok A., Barkhof F., Blankenstein M.A., Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging 2007, 28:1070-1074.
7. Buerger K., Otto M., Teipel S.J., Zinkowski R., Blennow K., DeBernardis J., Kerkman D., Schroder J., Schonknecht P., Cepek L., McCulloch C., Moller H.J., Wiltfang J., Kretzschmar H., Hampel H. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol. Aging 2006, 27:10-15.
8. Dolev I., Michaelson D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13909-13914.
9. Egensperger R., Kosel S., von E.U., Graeber M.B. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol. 1998, 8:439-447.
10. Engelborghs S., De V.K., Van de C.T., Vanderstichele H., Van E.B., Cras P., Martin J.J., Vanmechelen E., De Deyn P.P. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 2008, 29:1143-1159.
11. Engelborghs S., Dermaut B., Goeman J., Saerens J., Marien P., Pickut B.A., Van den B.M., Serneels S., Cruts M., Van B.C., De Deyn P.P. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J. Neurol. Neurosurg. Psychiatry 2003, 74:1148-1151.
12. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De Leenheir E., Martin J.J., Vanmechelen E., Van Broeckhoven C., De Deyn P.P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 2007, 130:2320-2326.
13. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1456-1465.
14. Grimmer T., Riemenschneider M., Forstl H., Henriksen G., Klunk W.E., Mathis C.A., Shiga T., Wester H.J., Kurz A., Drzezga A. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 2009, 65:927-934.
15. Hamalainen A., Grau-Olivares M., Tervo S., Niskanen E., Pennanen C., Huuskonen J., Kivipelto M., Hanninen T., Tapiola M., Vanhanen M., Hallikainen M., Helkala E.L., Nissinen A., Vanninen R.L., Soininen H. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. Neurodegener. Dis. 2008, 5:186-189.
16. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Moller H.J., Blennow K., Buerger K. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 2004, 9:705-710.
17. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
18. Herukka S.K., Hallikainen M., Soininen H., Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005, 64:1294-1297.
19. Herukka S.K., Helisalmi S., Hallikainen M., Tervo S., Soininen H., Pirttila T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 2007, 28:507-514.
20. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 2001, 297:187-190.
21. Kester M.I., Blankenstein M.A., Bouwman F.H., van Elk E.J., Scheltens P., van der Flier W.M. CSF biomarkers in Alzheimer's Disease and controls: associations with APOE genotype are modified by age. J. Alzheimers Dis. 2009, 16:601-607.
22. Levi O., Jongen-Relo A.L., Feldon J., Michaelson D.M. Brain area- and isoform-specific inhibition of synaptic plasticity by apoE4. J. Neurol. Sci. 2005, 229-230:241-248.
23. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del S.T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
25. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
26. Ophir G., Amariglio N., Jacob-Hirsch J., Elkon R., Rechavi G., Michaelson D.M. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol. Dis. 2005, 20:709-718.
27. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
28. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
29. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
30. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
31. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9649-9653.
32. Schoonenboom S.N., Visser P.J., Mulder C., Lindeboom J., van Elk E.J., Van Kamp G.J., Scheltens P.H. Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 2005, 11:8-13.
33. Szekely C.A., Breitner J.C., Fitzpatrick A.L., Rea T.D., Psaty B.M., Kuller L.H., Zandi P.P. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008, 70:17-24.
34. van der Flier W.M., Schoonenboom S.N., Pijnenburg Y.A., Fox N.C., Scheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006, 67:526-527.
35. Verhage F. Intelligentie en Leeftijd: Onderzoek bij Nederlanders van Twaalf tot Zevenenzeventig Jaar 1964, Van Gorcum, Assen.
36. Visser P.J., Kester A., Jolles J., Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006, 67:1201-1207.
37. Warzok R.W., Kessler C., Apel G., Schwarz A., Egensperger R., Schreiber D., Herbst E.W., Wolf E., Walther R., Walker L.C. Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis. Assoc. Disord. 1998, 12:33-39.